1	A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2,
2	despite low post-exposure prophylaxis efficacy and frequent viral rebound
3	
4	
5	Authors
6 7	Shadisadat Esmaeili, <sup>1*†</sup> Katherine Owens, <sup>1†</sup> Jessica Wagoner, <sup>2</sup> Stephen J. Polyak, <sup>2</sup> Judith M. White, <sup>3</sup> Joshua T. Schiffer <sup>1,2</sup>
8	
9	Affiliations
10	<sup>1</sup> Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA.
11	<sup>2</sup> Department of Medicine, University of Washington; Seattle, WA, USA.
12	<sup>3</sup> Department of Cell Biology, University of Virginia; Charlottesville, VA, USA.
13	*Corresponding Author: <u>sesmaeil@fredhutch.org</u>
14	<sup>†</sup> These authors contributed equally to this work.
15	
16	Abstract
17	In a pivotal trial (EPIC-HR), a 5-day course of oral ritonavir-boosted nirmatrelvir, given early
18	during symptomatic SARS-CoV-2 infection (within three days of symptoms onset), decreased
19	hospitalization and death by 89.1% and nasal viral load by 0.87 log relative to placebo in high-
20	risk individuals. Yet, nirmatrelvir/ritonavir failed as post-exposure prophylaxis in a trial, and frequent viral rebound has been observed in subsequent cohorts. We developed a mathematical
21 22	model capturing viral-immune dynamics and nirmatrelvir pharmacokinetics that recapitulated
22	viral loads from this and another clinical trial (PLATCOV). Our results suggest that
23 24	nirmatrelvir's <i>in vivo</i> potency is significantly lower than <i>in vitro</i> assays predict. According to
25	our model, a maximally potent agent would reduce the viral load by approximately 3.5 logs
26	relative to placebo at 5 days. The model identifies that earlier initiation and shorter treatment
27	duration are key predictors of post-treatment rebound. Extension of treatment to 10 days for
28	Omicron variant infection in vaccinated individuals, rather than increasing dose or dosing

29 frequency, is predicted to lower the incidence of viral rebound significantly.

- 30
- 31

#### 32 Introduction

The SARS-CoV-2 main protease inhibitor nirmatrelvir is a drug plagued by 33 contradictions. In a landmark, randomized, double-blinded, placebo-controlled clinical 34 trial with 1364 analyzed individuals, 300 mg of nirmatrelvir boosted with 100 mg 35 ritonavir was given twice daily for five days to high-risk individuals with SARS-CoV-2 36 infection within 3 days of developing symptoms. Compared to placebo, nirmatrelvir 37 reduced the combined outcome of hospitalization and death by 89%, eliminated death 38 as an outcome, and reduced viral load by 0.87 log after 5 days of treatment<sup>1</sup>. This 39 critical result prompted the Food and Drug Administration (FDA) to issue an 40 Emergency Use Authorization<sup>2</sup>. The drug became the most widely prescribed antiviral 41 for SARS-CoV-2 in the United States, likely preventing thousands of hospitalizations 42 and many deaths<sup>3</sup>. Ritonavir boosted nirmatrelvir was recently licensed by the FDA 43 based on its continued effectiveness and safety<sup>4</sup> and has outperformed other antivirals 44 in terms of hospitalization and viral load reduction<sup>5</sup>. 45

However, the use of nirmatrelvir/ritonavir in real-world cohorts has identified viral 46 rebound as a significant issue. Viral rebound occurred in 14.2% of individuals in one 47 large cohort and was usually associated with recrudescence of symptoms, though 48 protection against hospitalization and death appeared to be maintained<sup>6</sup> and remains 49 significant despite high rates of population immunity due to vaccination and prior 50 infection<sup>7</sup>. Similar rates of viral rebound were observed between molnupiravir and 51 nirmatrelvir, suggesting the rebound effect is not drug-specific and may pertain to 52 characteristics of SARS-CoV-2 infection and treatment duration<sup>8</sup>. This high incidence 53 54 of viral rebound exceeded the 2.3% rate observed in the proof-of-concept trial, which did not differ from placebo9. 55

Despite its high efficacy as an early symptomatic therapy for high-risk individuals, 56 nirmatrelvir/ritonavir was not authorized for use as post-exposure prophylaxis (PEP). In 57 a clinical trial of post-exposure prophylaxis, nirmatrelvir/ritonavir showed 32% and 58 37% reductions in symptomatic COVID-19 relative to placebo when given for five or 59 ten days respectively<sup>10</sup>. However, neither of these results reached statistical 60 significance. Notably, molnupiravir, another drug that reduced hospitalization when 61 given during early symptomatic infection, also failed as post-exposure prophylaxis<sup>11</sup>. 62 Only long-acting monoclonal antibodies have demonstrated efficacy for post-exposure 63 prophylaxis<sup>12-14</sup>, but these are no longer active against prevalent circulating strains<sup>15</sup>. 64

Early during the COVID-19 pandemic, multiple groups employed mathematical models 65 to simulate the outcomes of clinical trials for SARS-CoV- $2^{16-22}$ . These models all 66 accurately predicted that antiviral therapy that was insufficiently potent or given too 67 late during infection might fail to provide clinical benefit<sup>16–19,21</sup>. Our previous modeling 68 results further suggested that viral rebound may occur and was more likely if a drug 69 was dosed during the pre-symptomatic phase of infection when viral loads are still 70 expanding, as occurs in a post-exposure prophylaxis scenario<sup>23</sup>. The proposed 71 mechanism of this effect was that reducing viral load may blunt early immune 72 responses and preserve susceptible cells, allowing viral re-expansion upon cessation of 73 treatment that was of insufficient potency to eliminate all infected cells<sup>24</sup>. The model 74 75 suggested that this phenomenon could theoretically occur during early symptomatic treatment as well. At the time, we downplayed the significance of model-generated 76 rebound as the phenomenon had yet to be demonstrated clinically. However, models fit 77 78 to rebound data now suggest a similar mechanism of action<sup>25</sup>.

Here we use an updated model for SARS-CoV-2 viral kinetics that was first validated 79 80 against a much larger panel of untreated individuals to precisely simulate the virologic outcomes of two nirmatrelvir/ritonavir trials. We identify that the true in vivo potency 81 of nirmatrelvir is significantly less than its *in vitro* potency, such that drug levels are 82 sub-therapeutic during a portion of the dosing interval. Viral rebound is observed in our 83 simulations and is more likely when the drug is dosed early during infection and is not 84 reduced with a higher dose or dosing frequency. Extended-duration treatment is 85 identified as the best strategy to avoid viral rebound. 86

88 Results

87

#### 89 Viral Dynamic, Pharmacokinetic, and Pharmacodynamic Mathematical models

To derive parameters for simulating nasal viral loads in the absence of therapy, we used 90 the mechanistic mathematical model (Fig 1a) that best recapitulated 1510 SARS-CoV-91 92 2 infections in a cohort of 1440 SARS-CoV-2 infected individuals from the National Basketball Association cohort<sup>26</sup>. The model assumes a finite number of susceptible 93 cells. An eclipse phase delays viral production by infected cells. In keeping with an 94 early interferon-mediated innate immune response, susceptible cells can become 95 refractory to infection in the presence of infected cells but also revert to a susceptible 96 state at a constant rate. Infected cells are cleared by cytolysis, a constant early immune 97 response rate, and delayed acquired immunity, which is activated in a time-dependent 98 fashion. We used a mixed-effect population approach implemented in Monolix to 99 100 estimate model parameters (Fig S1, Table S1).

To reproduce levels of nirmatrelvir, we used a two-compartment pharmacokinetic (PK) 101 model (Error! Reference source not found.b). Using Monolix and the mixed-effect 102 population approach, we estimated parameter values by fitting the model to the plasma 103 concentration of healthy subjects. The model closely recapitulated observed drug levels 104 following a single dose of 250mg/100mg of nirmatrelvir/ritonavir (Fig S2, Table S2). 105 The effect of ritonavir as a metabolic inhibitor is accounted for in nirmatrelvir's 106 clearance rate in the PK model. We also fit the model to population-level plasma 107 concentrations following a single dose of 250mg/100mg and 750mg/100mg, showing 108 that estimated parameters are dose-independent (Table S3). 109

- For the pharmacodynamic (PD) model, we assumed drug efficacy follows a Hill equation with respect to concentration. We parameterized the model using *in vitro* efficacy data collected at different concentrations of nirmatrelvir (details in **Materials and Methods, Fig S3, Table S4**).
- Finally, we combined the viral dynamic and PKPD models by using treatment efficacy to lower the viral production rate (details in **Materials and Methods, Fig 1**). We fit the
- 116 combined model to viral load drop from baseline reported in two randomized,
- 117 controlled trials: the EPIC-HR trial with 1574 high-risk unvaccinated symptomatic
- individuals<sup>1</sup> (Fig 2) and the PLATCOV trial with 144 low-risk, symptomatic
- individuals (Fig 3a-e) <sup>5</sup>. We also fit the combined model to individual viral load data
   from PLATCOV (Fig 3f-h, Fig S4 & Fig S5, Table S5).

#### 121 Mathematical model fitting to clinical trial virologic outcome data

- 122 The *in vivo* potency of a drug is often different from values measured *in vitro*<sup>23,28,29</sup>. We 123 define the *in vivo* IC<sub>50</sub> as the plasma drug concentration required to inhibit viral
- replication by 50% and the potency reduction factor (prf) as the ratio between the *in*

- *vivo* and *in vitro* IC<sub>50</sub>. To identify the *in vivo* potency of nirmatrelvir, we estimated the
  prf using two methods.
- For the first method, we simulated virtual cohorts using the combined viral dynamic-PKPD model and fit the results to viral load decay from baseline in two trials. For each trial arm, we randomly selected 400 individuals from the NBA cohort with the closest matching viral variant, symptom, and vaccine status (unvaccinated symptomatic subgroup for EPIC-HR and symptomatic Omicron infection for PLATCOV) and used their estimated individual viral dynamic parameters in simulations. This approach generated a wide, realistic range of shedding kinetic patterns among simulated
- 134 participants (**Fig S1**).
- We next addressed variability in the timing of baseline viral load measurement relative to infection. We randomly assigned all individuals an incubation period selected from a variant-specific gamma distribution found in the literature.<sup>27</sup> Treatment start day was randomly selected from a uniform distribution for each individual within 3 days of symptom onset for EPIC-HR trial and within 4 days for the PLATCOV trial.
- For all simulated individuals in the treatment arm, PK parameters were randomly drawn from the estimated lognormal population parameter distributions (**Table S2**) and PD parameters from a normal distribution with estimated mean and standard error (**Table S4**). To estimate the prf, we simulated our virtual cohort treated with 300 mg of nirmatrelvir twice per day for five days with a range of values and selected the prf that generated the best agreement between the average change from baseline in the treatment arm of each trial and each simulation.
- 147Our simulations recapitulated the mean change in viral load from baseline to multiple148timepoints during the two weeks following study enrollment in EPIC-HR (Error!149Reference source not found.a) and PLATCOV (Fig 3a). Similarly, with optimized prf150estimates, the model closely recapitulated mean viral load reduction in the treatment151arms of both trials (Figs 2b and 3b).
- 152 Our model also predicted individual-level variability in virologic responses observed in
- 153 PLATCOV, including instances of increased viral load following therapy. We
- compared simulated and actual distributions of viral load change among trial
   participants in the control and treatment arms. On most post-treatment days, simulated
- participants in the control and treatment arms. On most post-treatment days, simulated
   and actual distributions were not statistically dissimilar (Fig 3d, e). Wider distributions
- 157 of observed versus simulated viral load change were noted on post-randomization days
- 157 1 and 2 for control and days 1 and 4 for treatment (**Fig 3d, e**), perhaps due to noise in
- viral load data from oral swabs: differences of 1-2 logs were often noted between
- replicates collected from PLATCOV participants at equivalent timepoints, particularly
- 161 on day 1 and 2 (**Fig S6**).

#### 162 **Reduction of** *in vivo* **nirmatrelvir potency relative to** *in vitro*

- We plotted the coefficient of determination, R<sup>2</sup>, for fit to viral load data assuming different prf values (**Figs 2c and 3c**). The best values (prf=61 for EPIC-HR and prf=37 for PLATCOV) were determined by maximizing the R<sup>2</sup> of the fit. We repeated the simulation 10 times: the boxplot in the lower panel of **Figs 2c** and **3c** represents the standard error of the prf average value and does not reflect individual variability.
- 168 The reason for slight differences in estimated prfs between the two trials is unknown. 169 Possible explanations include different sampling methods (nasal swabs in EPIC-HR 170 versus oropharyngeal swabs in PLATCOV), different trial participant characteristics

(high-risk adults in EPIC-HR versus lower-risk adults without comorbidities in
PLATCOV), and differing dominant viral variants between the trials.

#### 173 Mathematical model fitting to individual viral load trajectories in PLATCOV

For the second method, we fit the combined viral dynamic-PKPD model to individual 174 viral load data from the PLATCOV trial. Since samples were collected after 175 enrollment, we also included data from symptomatic Omicron-infected individuals in 176 the NBA cohort to inform the population model about viral expansion rates during 177 early infection. We used a mixed-effect population approach in Monolix to estimate 178 179 each participant's viral dynamic parameters and their potency reduction factor (prf) (details in Materials and Methods). Our model closely recapitulated viral load 180 trajectories, including cases with post-treatment rebound (Fig 3f-g). The estimated 181 individual prf values were lognormally distributed, with a median of 39.79 (IOR 27.25-182 55.75, range 13.51-105.03) (Fig 3h, Table S5). 183

- The estimated population distribution of viral load parameters for Omicron-infected 184 individuals of the NBA cohort and the PLATCOV trial were the same except for  $\phi$  (a 185 proxy for the innate immune response),  $\tau$  (timing of the adaptive immune response), 186 and  $t_0$  (infection time) (Fig S7). Time is measured relative to the day of detection in the 187 NBA cohort and relative to the day of baseline measurement in the PLATCOV trial, so 188 the larger  $t_0$  and  $\tau$  values for PLATCOV reflect the delay between infection and trial 189 enrollment. The reason for slight differences in estimated  $\phi$  values between the two 190 191 groups is unknown but might be due to the different sampling methods (nasal swabs for NBA versus oropharyngeal swabs for PLATCOV). 192
- 193 To further validate our model, we ran counterfactual simulations switching the PLATCOV treatment and control arms (Fig S8 c & d). We treated participants in the 194 control arm of the trial (treatment counterfactual) and removed treatment from 195 196 participants in the treatment arm (control counterfactual). Due to treatment effect, onset of the adaptive immune response was not easily identifiable for the treatment arm. 197 198 Therefore, when running the control counterfactual simulation, we assigned random  $\tau$  values from the estimated control arm distribution. Counterfactual simulations 199 reproduced the mean viral load drop from baseline observed in the trial (Fig S8a & b) 200 and predicted a diversity of responses to treatment. In some cases, treatment lowered 201 the peak and shortened infection (Fig S8c(I) & d(III)), while in other cases, treatment 202 had a more limited effect (Fig S8c(IV) & d(II)). Our results suggest that some 203 individuals with treatment-induced rebound may not have rebounded in their 204 counterfactual case (Fig S8c(III)), while some untreated individuals with persistent 205 206 infection might have experienced a treatment-induced rebound (Fig S8d(I)).
- 207

#### 208 Estimates of viral load reduction with an optimal drug

To illustrate the importance of estimating *in vivo* drug potency, we compared the PKPD 209 projection and average change in viral load of treatment arms with prf=1 (no reduction 210 in potency) and prf=61 (as estimated in the EPIC-HR trial). With an approximately 61-211 fold weaker potency, drug levels dropped below therapeutic level shortly after each 212 dose, due to its short half-life  $(t\frac{1}{2})$ , and antiviral effect subsided within a day after 213 treatment ended maintaining an average efficacy of 82% (eq. 3) over the first 5 days of 214 treatment (Fig 2d, e). However, the plasma concentration of a perfectly potent drug 215 (prf=1) remained above therapeutic levels for the duration of treatment with a 5-day 216 average efficacy of 99.99% and the effect persisted for nearly 10 days (Fig 2e). If the in 217 vivo potency perfectly matched the measured in vitro potency (prf=1), the same 218

- 219treatment regimen could reduce the viral load by approximately 3.5 logs at day 5220relative to the placebo compared to the 0.87 log reduction reported in the trial (**Fig 2f**).221While estimating nirmatrelvir's *in vitro* PD parameters, we assumed only the IC<sub>50</sub>222differs *in vivo*. To confirm the validity of this assumption, we simulated the treatment223arm of EPIC-HR with different combinations of the prf and the Hill coefficient. Fig S9224shows that the best fit always happened for prf ~60 and was mostly independent of the225Hill coefficient.
- The potency reduction factor was more sensitive to certain PK parameters (Fig S10), particularly the drug's clearance rate ( $\kappa_{CL}$ ). If the drug was cleared from the body more rapidly-then it would need to be more potent to achieve the effect observed in the clinical trial. However, this did not impact our alternate dosing regimen simulations since PK parameters were independent of the dose (Table S3).

#### 231 Frequent viral rebound on nirmatrelvir

- To assess whether our model generated viral rebound, we assumed cohort 232 characteristics compatible with the PLATCOV trial (Fig 3) and randomly drew 233 individual prf values from the distribution obtained by fitting individual data (Fig 3h, 234 235 Table S5). We simulated from infection to 30 days after symptom onset, monitoring viral load continually. We defined rebound in the control arm as any case with at least 236 two peaks in viral load with height greater than 3 logs and higher than its preceding 237 minimum by at least 1 log (Fig S11a). We defined rebound in the treatment arm as any 238 instance in which a post-treatment viral load exceeded the viral load at the end of the 239 treatment by 1 log (Fig S11b). 240
- By this definition, we observed rebound in 18.15% of cases treated with the clinical trial dose and 1.75% of controls in our simulations (**Fig 4b**). When a less sensitive equivalent definition of rebound was used as in the trial (1 log increase in viral load 5 days after treatment cessation), the probability of rebound in the simulation was much lower (4.12% if treatment was assumed to begin several days after symptoms), closer to that of the controls, and comparable to that observed in the trial (**Fig S12**).

#### 247 Limited impact of nirmatrelvir dose or dosing frequency on viral rebound

- We next explored different treatment regimens to estimate their impact on lowering viral load and the chance of rebound. We simulated therapy with 150, 300, 600, and 900 mg doses administered twice per day for 5 days, starting within 3 days post symptom onset. Larger doses decreased viral load more significantly and quickly than 300 mg twice daily. 900 mg of nirmatrelvir reduced viral load by a mean of 2 logs on day 2 and a mean of 4 logs on day 5 compared to the control (**Fig 4a**).
- Individual viral loads were highly variable within each treatment group regardless of 254 dose (Fig 4a) due to heterogeneous underlying viral dynamics (Fig S1) and different 255 treatment timing. Responses to treatment also differed substantially according to viral 256 load trajectory and treatment timing (Fig 4c). The reduction in viral load was almost 257 258 always greater during the first 5 days of treatment with higher doses. However, this only impacted viral elimination in certain cases (Fig 4c,i). Sometimes, viral load 259 equilibrated to similar levels post-treatment regardless of dose (Fig 4c, ii), while in 260 other cases, higher doses were associated with rebound (Fig 4c, iv). By achieving a 261 lower post-treatment viral load nadir, higher doses resulted in a greater likelihood of 262 viral rebound in our simulations (Fig 4b). 263
- Increasing the frequency of antiviral dosing had nearly equivalent effects to increasing the dose: a more rapid reduction in viral load (Fig S13a), heterogeneous effects based

on individual viral dynamics and treatment timing (Fig S13c), and increased chance of
 rebound (Fig S13b).

#### 268 Early treatment as a predictor of SARS-CoV-2 rebound

We next simulated therapy with four different treatment initiation windows: postexposure prophylaxis (PEP): 0-1 day after infection in the pre-symptomatic phase; early treatment: 0-1 day after symptom onset as often occurs in community settings; intermediate treatment: 1-5 days after symptom onset as in the clinical trial; and late treatment: 5-10 days after symptom onset. In all simulations, the administered dosage was 300mg twice per day for 5 days.

Applying treatment as PEP or shortly after symptoms lowered viral load more substantially relative to control than intermediate or late therapy at days 2 and 5 posttreatment, though intermediate and late strategies also significantly lowered viral load relative to control at these time points (**Fig 5a**). However, PEP and early treatment were associated with higher rebound probability after treatment (**Fig 5b, c**). The boxplots for control groups in each panel in **Fig 5a** show the viral load at different points during infection and are matched to different timing of nirmatrelvir in the treatment arms.

#### 282 **Prolongation of treatment to reduce the probability of SARS-CoV-2 rebound**

- Next, we analyzed the impact of treatment duration on viral rebound. We simulated 283 treatment regimens with 300mg nirmatrely twice per day for 2, 5, 10, 15, and 20 days. 284 Treatment was initiated within 3 days after symptoms appeared. Fig 6a demonstrates 285 the continuous drop in viral load if treatment was maintained until infection was 286 effectively cleared. The viral load distributions of the treatment arms with 15 and 20 287 days of treatment on days 2, 5, and 10 matched the viral load distribution of the 288 treatment arm with 10 days of treatment duration and, therefore, are not shown. 289 Prolonging treatment duration to 10 days almost eliminated viral rebound (Fig 6b & c). 290
- We next explored the impact of treatment duration given different treatment initiation time. Prolonging treatment to 15 days for early treatment and 20 days for PEP lowered the viral load close to the limit of detection (1.26 log) at the end of treatment and eliminated the probability of rebound for Omicron variants (**Fig 7**).

## Differing observed rebound rates resulting from varying timing of sampling and definitions

Previous studies defined rebound using criteria with varying virologic thresholds, 297 timing, and sampling frequency <sup>9</sup>. Rebound was sometimes defined when a positive test 298 followed a negative test <sup>30</sup>. In EPIC-HR, treatment started within 5 days of symptoms 299 onset (our intermediate treatment group) and rebound was defined as a 0.5 log increase 300 on days 10 and/or 14. By this definition 2.3% of treated cases were classified as 301 rebound  $^{9}$ . The probability of rebound in our simulation with a threshold of 0.5 log 302 measured only on day 5 after the end of the treatment was 5.45% and decreased as 303 thresholds for viral rebound increased (Fig S12). This percentage would be even lower 304 if treatment started 3-5 days after symptoms (rather than 1-5 days) because rebound 305 probability is very sensitive to treatment timing. We hypothesize that in EPIC-HR, 306 307 participant enrollments skewed later during the 5-day post-symptom window.

- In our simulations, we recorded viral load every 0.001 of a day and used a 1 log threshold to identify rebound cases. This was a more sensitive method to observe rebound and suggests that in trial and real-world cohorts, rebound is likely more common in treated individuals than is detected with less frequent sampling (**Fig S12**).
  - Page 7 of 26

312

# Higher rebound probability in unvaccinated individuals with pre-Omicron variant infection

All simulations reported in **Figures 3-7** were performed assuming symptomatic, 315 vaccinated individuals with Omicron infection in the NBA cohort or PLATCOV. We 316 repeated simulations with characteristics compatible with the EPIC-HR trial 317 (unvaccinated symptomatic individuals with pre-Omicron variants) and prf values 318 randomly drawn from the distribution obtained in **Fig 2c**. The same patterns of rebound 319 320 probability were observed for altered treatment regimens. However, our model predicted an overall higher rebound probability in unvaccinated individuals, infected by 321 pre-Omicron variants (FigS14). While 10 days of treatment would be sufficient to 322 lower the rebound probability significantly in the vaccinated individuals with Omicron 323 infection, 15 days of treatment would have been necessary to substantially lower the 324 incidence of rebound in unvaccinated individuals in the pre-omicron era. 325

326

#### 327 Immune and viral mechanisms for viral rebound

To understand mechanisms that might explain higher rebound incidence in the PEP and 328 early treatment groups, we simulated four treatment arms with treatment starting on 329 days 1, 4, 7, and 10 after infection. Treatment start relative to infection was fixed to 330 limit the added variability introduced by incubation period and timing of treatment 331 relative to symptoms in previous simulations. High frequency of rebound with day 1 332 and day 4 treatment start was evident from viral load after treatment (Fig 8a top row) in 333 many individual trajectories (grey lines) and to a less dramatic extent in mean viral load 334 (blue line). A second peak after treatment ended was also seen in infected cells (Fig 8a 335 middle row, blue line) and the intensity of the innate immune response (the rate of 336 production of refractory cells) (Fig 8a bottom row). 337

- Applying treatment earlier during infection (day 1 and 4 in our simulations) lowered 338 the viral load and the populations of infected and refractory cells, preserving 339 susceptible cells. In the earlier treatment groups the ratio of susceptible to refractory 340 cells was significantly higher at the end of the treatment than it was in the control group 341 at equivalent time points (Fig 8b). Innate immune responses were significantly 342 diminished in treated individuals versus controls due to fewer infected cells (Fig 8c). 343 Overall, a weaker innate immune response, higher availability of susceptible cells, and 344 persistence of infected cells after 5 days of treatment allowed viral rebound after 345 treatment cessation. 346
- We previously partitioned the NBA cohort according to shedding kinetics using kmeans clustering<sup>26</sup>. Groups were ordered by the area under their viral load curve (AUC), with group 1 having the smallest AUC and group 6 the largest (**Fig S15a**). We simulated treatment with different initiation days using these 6 groups and identified the highest rebound probability in the earlier treatment groups when treating infections that would have fast initial virus expansion (upslope) and high peak viral load (groups 2, 4, and 6) without treatment (**Fig S15b, c**).

#### 355 Discussion

354

We previously demonstrated for HSV-2<sup>31</sup>, HIV<sup>32</sup>, Ebola virus<sup>28</sup>, and SARS-CoV-2<sup>23</sup>, that considering the timing and intensity of the immune response is vital to accurately simulate clinical trials of antiviral agents. If a direct-acting antiviral therapy is given too

late during infection, then efficacy is often low because the disease is driven by excess 359 inflammation and cytokine storm. On the other hand, concurrent immune pressure can 360 provide critical assistance for antiviral agents to eliminate viral replication, as 361 confirmed in recent studies7. Accordingly, previous modeling suggested that extremely 362 early treatment of pre-symptomatic SARS-CoV-2 as occurs with PEP requires higher 363 drug potency than treatment during early symptomatic infection because innate 364 immunity is more active at this slightly later stage of infection and fewer susceptible 365 cells remain<sup>23</sup>. It is increasingly clear that the potency and duration of antiviral therapy 366 required to achieve clinical benefit depends strongly on the stage of infection and the 367 ongoing intensity of the immune response. 368

- Prior work also demonstrated that *in vitro* antiviral drug potency measured in cell 369 culture often overestimates *in vivo* potency in humans<sup>28,29,33</sup>. Specifically, the plasma 370 drug level required to achieve 50% inhibition of cellular infections in vivo is higher 371 than the level required in vitro. The discrepancy between in vitro and in vivo potency 372 can be assessed by fitting viral dynamic-PKPD mathematical models to viral load data 373 from clinical trials, as we have done here. Traditional PKPD models, which do not 374 include a dynamic immune response, are not sufficient to estimate *in vivo* potency. 375 Because *in vivo* potency reduction varies from 2 to 100 depending on the infection and 376 antiviral agents<sup>28,31,33</sup>, population *in vivo*  $IC_{50}$  must be assessed separately in each case. 377
- Here, by precisely fitting a combined viral-immune dynamic / PKPD model to viral 378 load data from a randomized clinical trial as well as an open-label clinical trial of 379 nirmatrelvir/ritonavir, we merge these two key concepts. We first identify that 380 nirmatrelvir potency is reduced 60-70 fold in vivo relative to in vitro in the high-risk 381 population and 30-40 fold in the healthy population. The difference between the 382 estimated *in vivo* potency in these two populations might be explained by differences in 383 demographics, sampling methods, and the dominant viral variants in the two trials. 384 However, both values fall within the range of inter-individual variability estimated by 385 fitting the model to the individual viral loads of the second trial. The mechanistic 386 reasons for this reduction cannot be determined by the model, but may include 387 increased *in vivo* protein binding<sup>34</sup>, inhibition of drug delivery from plasma to sites of 388 389 infection, or differences in cellular uptake and drug metabolism in vivo<sup>35</sup>. Nevertheless, our estimated *in vivo*  $IC_{50}$  provides a benchmark plasma level to target in future trials. 390 The PKPD model also demonstrates that the drug's relatively short half-life allows it to 391 dip to subtherapeutic levels even when dosed twice daily. 392
- Our model also develops a viable hypothesis for why nirmatrelvir is highly effective 393 394 when given during early symptomatic infection but less so when given as post-exposure prophylaxis. By preventing a high peak viral load approximately 3-5 days after 395 infection, therapy preserves susceptible cells and blunts the immediate, likely innate 396 397 immune response to SARS-CoV-2, while not eliminating infected cells. If the virus is not eliminated by an early acquired response along with antiviral pressure, it rebounds 398 to a peak level that is sometimes comparable to the initial peak. We hypothesize that 399 viral rebound occurs more frequently in community settings relative to the clinical trial, 400 because infected individuals in the community are often prescribed the drug very early 401 after symptom development, whereas in the trial, there was a natural 1 to 2-day delay 402 based on the enrollment and consent process. Surprisingly, this short delay may have 403 limited rebound while not affecting the primary endpoints of the trial, a finding 404 supported by recent clinical studies<sup>30</sup>, which nevertheless still suggests a clear benefit 405 for earlier treatment in terms of preventing hospitalization in high-risk individuals<sup>7</sup>. 406 Notably, antiviral therapy is not a risk factor for rebound in our model or in clinical 407

- 408 cohorts if administered late during infection<sup>36</sup>. However, high viral load shedding is a
   409 risk factor for rebound in our model, as suggested in other studies <sup>37</sup>.
- Our model identifies optimal conditions for viral rebound, which, counterintuitively, 410 include early treatment during pre-symptomatic infection and higher or more frequent 411 dosing. Both factors suppress-the amount of infection, thereby preserving susceptible 412 cells, limiting the development of refractory cells, and dampening the intensity of the 413 early immune response. The best method to prevent viral rebound is prolonging 414 treatment, with a longer course needed for PEP. This finding is consistent with trials of 415 long-acting monoclonal antibodies, which demonstrated efficacy as post-exposure 416 prophylaxis<sup>12-14</sup>. 417
- Because our model is validated precisely against mean viral load reduction from two 418 trials as well as individual viral kinetics it can be used as a tool to test treatment 419 strategies varied therapeutic goals, timing of treatment, dose, dosing interval, and 420 duration of therapy. Our prior PD modeling also allows testing of potentially 421 synergistic agent combinations and consideration of special hosts such as 422 immunocompromised individuals with persistent infection who may be at risk of 423 developing drug resistance<sup>28,38,39</sup>. We believe our approach provides a template for 424 optimizing future trial designs with nirmatrelvir and other therapies. 425
- Our model has several limitations. First, nasal or oropharyngeal viral load is not a 426 perfect surrogate of disease activity. On the one hand, viral load reduction has been 427 correlated with beneficial clinical outcomes for nirmatrelvir<sup>1</sup>, molnupiravir<sup>40</sup>, and 428 monoclonal antibodies<sup>41</sup>. A recent review shows that viral load reduction is a 429 reasonably good surrogate endpoint<sup>41</sup>. Moreover, viral rebound appears to track very 430 closely with symptomatic rebound in multiple case series<sup>9</sup>. Yet, early remdesivir 431 treatment provided a profound reduction in hospitalization while not impacting nasal 432 viral load, albeit 5 days after completion of therapy<sup>42</sup>. Data from non-human primates 433 suggests that the drug has a specific effect on viral loads in the lungs that is not 434 observed in upper airways, a finding that we were  $also^{23}$ . Overall, there is a strong 435 suggestion from early treatment trials that a reduction in nasal viral loads beyond that 436 observed in placebo-treated individuals is associated with substantial clinical benefit<sup>1</sup>. 437
- Another limitation is that the model does not account for drug resistance. While there
  has been limited evidence of de novo resistance during nirmatrelvir therapy, serial
  passage of virus suggests a relatively low barrier, and some viral rebound could, in
  theory, be with resistant variants. Studies to date suggest very little mutational change
  between the infecting and rebounding virus<sup>43-46</sup>.
- Our model does not capture immunity in literal terms. For instance, we do not 443 distinguish innate interferon, antibody, and T-cell responses, as these have not been 444 measured in sufficient longitudinal detail to precisely ascribe viral clearance to different 445 components of the immune response. We structured the model for the early response to 446 447 roughly map to innate responses, as the model term capturing the progression of susceptible cells to a refractory state diminishes with decreases in viral load and 448 449 assumes no immune memory. The late immune response in our model has memory, leads to rapid elimination of the virus, and is likely to represent acquired immunity. 450 While a more accurate model would discriminate different arms of the immune 451 responses and fit to immune data, ours sufficiently captures the timing and intensity of 452 453 immune responses for accurate clinical trial simulation.
- 454 Finally, it is our opinion that models lacking a spatial component cannot fully describe 455 target cell limitation, which is influenced by the packing structure of cells, viral

- diffusion, and infection within multiple concurrent micro-environments<sup>31</sup>.
- 457 Consequently, ordinary differential equations may misclassify the relative impact of 458 target cell limitation and innate immune responses in the period surrounding peak viral 459 load. However, our approach provides accurate output for clinical trial simulation.
- 460 In conclusion, our model identifies viable mechanistic underpinnings of the high 461 efficacy of nirmatrelvir therapy for early symptomatic SARS-CoV-2 infection, lower 462 efficacy for PEP, and high incidence of viral rebound in a real-world setting. The model 463 can also be used to assess different treatment strategies and suggests prolonging therapy 464 is the optimal method to avoid rebound while maintaining potent early antiviral 465 suppression.
- 466

#### 467 Materials and Methods

#### 468 Study Design

We developed a viral dynamics model recapitulating viral load data collected from 469 symptomatic individuals in the NBA (National Basketball Association) cohort<sup>47</sup>. We 470 used a two-compartment model to reproduce the PK data of nirmatrelvir plus ritonavir<sup>2</sup>. 471 For clinical trial simulation, we constructed a virtual cohort by randomly selecting 400 472 individuals from the NBA cohort, trying to match the trial populations regarding 473 vaccine status and history of infection, and assigning individual PK and PD parameters 474 randomly drawn from their respective inferred distributions. We fit the combined viral 475 dynamic and PKPD model to the average change in viral load from the baseline as well 476 as individual viral load data of the control and treatment arms of two previously 477 published nirmatrelvir/ritonavir clinical trials <sup>1,5</sup>. Comparing our model to the control 478 arms validated our viral dynamic model and demonstrated how well our virtual cohorts 479 represent the trial control arms. As one method of fitting the treatment arms, we used 480 the average data from the treatment arms to estimate the potency reduction factor (prf) 481 by maximizing the  $R^2$  of the fit. In a second approach, we fit to individual viral load 482 trajectories in PLATCOV using the mixed-effect population approach implemented in 483 Monolix and obtained both individual prf values and a population distribution. With the 484 estimated prf and *in vivo*  $IC_{50}$  of the drug, we explored different treatment regimens by 485 changing dose, dosing frequency, treatment duration, and treatment timing to find the 486 best strategy to minimize the probability of rebound. 487

#### 488 Viral load data

The NBA cohort dataset published by Hay et al<sup>47</sup> consists of 2875 documented SARS-CoV-2 infections in 2678 people detected through frequent PCR testing regardless of symptoms. We used the viral load data from 1510 infections in 1440 individuals that had at least 4 positive quantitative samples to estimate viral dynamic parameters. We used parameter sets estimated for the symptomatic subpopulation of these individuals to construct virtual cohorts.

#### 495 Clinical trial data

We used viral load data from two nirmatrelvir/ritonavir clinical trials. EPIC-HR by Hammond et al.<sup>1</sup> included 682 and 697 symptomatic high-risk individuals in the control and treatment arms, respectively. We obtained the average change in viral load data of the control and treatment arms by digitizing Figure 3A of the manuscript by Hammond et al.<sup>1</sup>. Nasal viral load was measured using PCR assay on days 0, 3, 5, 10, and 14 after the treatment start day and adjusted by the baseline viral load. PLATCOV by Schilling et al.<sup>5</sup> is an open-label, randomized, controlled adaptive trial with 85 and 59

symptomatic, young, healthy individuals in the control and nirmatrelvir treatment arms, 503 504 respectively. The oropharyngeal samples from each participant were collected daily on days 0 through 7 and on day 14 after the treatment start day, and viral load was 505 measured using PCR assay. We used the individual viral load data published by the 506 authors. From PLATCOV, we averaged over the two oral samples collected from each 507 individual and calculated viral load drop from baseline (to use in method 1, Figure 3) or 508 used the individual-level viral load data (in method 2, Figure 3). In both trials, the study 509 participants were treated with 300mg/100mg nirmatrelvir/ritonavir within three days 510 (EPIC-HR) or four days (PLATCOV) of symptom onset. The treatment was 511 administered twice per day, for five days. We used EPIC-HR's lower limit of detection 512  $(LOD = 2 \log imputed as 1 \log)$  in the simulations where we used EPIC-HR cohort 513 characteristics (unvaccinated symptomatic individuals) (Figures S9, S10, and S14). 514 When fitting to PLATCOV cohort characteristics (vaccinated symptomatic individuals 515 with omicron infection) and in all the simulations in the main paper, we used the 516 517 maximum LOD reported in the published data ( $\sim 1.26 \log$ ).

#### 518 PK data

PK data of nirmatrelvir (PF-07321332) with ritonavir was obtained by digitizing Figure
4 of the drug's Emergency Use Authorization document<sup>2</sup> using WebPlotDigitizer<sup>48</sup>.
The data is from a phase I randomized trial by Singh et al.<sup>49</sup> where eight participants (4
fed, 4 fasting) took a single dose of 250mg/100mg nirmatrelvir/ritonavir. Drug
concentrations in plasma were recorded for 48 hours following dosing.

#### 524 PD data

The data on drug efficacy experiments performed at the University of Washington. The 525 efficacy of nirmatrelvir in the presence of CP-100356 (an efflux inhibitor <sup>50</sup>) was 526 527 measured against the delta variant of SARS-CoV2 in Calu-3 cells (human lung epithelial). The efflux inhibitor ensures consistent, adequate intracellular levels of drug. 528 Briefly, Calu 3 cells were treated with varying concentrations of nirmatrelvir in the 529 presence of 2uM CP-100356 prior to infection with SARS-CoV-2 (delta isolate) at a 530 multiplicity of infection of 0.01. Antiviral efficacy and cell viability (of non-infected 531 cells treated with drugs) were assessed as described<sup>51</sup>. There were five replicates per 532 condition, pooled from 2 independent technical experimental repeats (one experiment 533 with triplicate conditions, one experiment in duplicate conditions). 534

#### 535 Viral dynamics model

We used our model of SARS-CoV-2 dynamics<sup>26</sup> to model the viral load of 536 symptomatic individuals with SARS-CoV-2 infection. Our model assumes that 537 susceptible cells (S) are infected at rate  $\beta VS$  by SARS-CoV-2 virions. The infected 538 cells go through a non-productive eclipse phase  $(I_F)$  before producing viruses and 539 transition to becoming productively infected  $(I_P)$  at rate  $\kappa I_E$ . When encountering 540 productively infected cells, the susceptible cells become refractory to infection (R) at 541 the rate  $\phi I_P S$ . Refractory cells revert to a susceptible state at rate  $\rho R$ . The productively 542 infected cells produce virus at the rate  $\pi I_P$  and are cleared at rate  $\delta I$  representing 543 cytolysis and the innate immune response that lacks memory and is proportional to the 544 amount of ongoing infection. If the infection persists longer than time  $\tau$ , then cytotoxic 545 acquired immunity is activated, which is represented in our model by the rate  $mI_P$ . 546 Finally, free virions are cleared at the rate  $\gamma$ . Of note, this model, previously proposed 547 by Ke et al. <sup>52</sup>, was selected against other models in<sup>26</sup> based on superior fit to data and 548 parsimony. The model written as a set of differential equations has the form, 549

550

551 
$$\frac{dS}{dt} = -\beta SV - \phi I_P S + \rho R$$
(1a)

552 
$$\frac{dR}{dt} = \phi I_P S - \rho R \tag{1b}$$

553 
$$\frac{dI_E}{dt} = \beta SV - \kappa I_E \tag{1c}$$

554 
$$\frac{dI_P}{dt} = \kappa I_E - \delta I_P - m(t)I_P$$
(1d)

555 
$$\frac{dV}{dt} = \pi I_P - \gamma V \tag{1e}$$

556 where 
$$\begin{cases} m(t) = 0 & t < \tau \\ m(t) = m & t \ge \tau \end{cases}$$
 (1f)

557

To estimate parameter values, we fit the model to viral load data from the NBA cohort using a mixed-effect population approach implemented in Monolix. Details on the model selection and fitting process can be found in Owens et al<sup>26</sup>. Information about parameter distributions and the error model is provided in **Table S1**.

562 We start the simulations with  $10^7$  susceptible cells. The initial value of the refractory 563 cells is assumed to be zero since the interferon signaling is not active prior to infection. 564 We further assume there are no infected cells (eclipse or productive) at the beginning of 565 the infection. We fix the level of inoculum ( $V_0$ ) at 97 copies/ml for each individual.

To resolve identifiability issues, we fixed two parameter values, setting the inverse of the eclipse phase duration to  $\kappa = 4$ , and the rate of clearance of virions to  $\gamma = 15^{26}$ .

#### 568 PK model

569 We used a two-compartmental PK model which includes the amount of drug in the GI 570 tract  $(A_{GI})$ , the plasma compartment  $(A_p)$ , and the lung  $(A_L)$ . The drug is administered 571 orally, passes through the GI tract and gets absorbed into the blood at the rate  $\kappa_a$ . The 572 drug then transfers from the blood into the peripheral compartment (or the lung) at the 573 rate  $\kappa_{PL}$ . The metabolized drug transfers back into the plasma at the rate  $\kappa_{LP}$  from 574 where it clears from the body at the rate  $\kappa_{CL}$ . The model in the form of ordinary 575 differential equations is written as,

576 
$$\frac{dA_{GI}}{dt} = -\kappa_a A_{GI} \tag{2a}$$

$$\frac{dA_P}{dt} = \kappa_a A_{GI} + \kappa_{LP} A_L - (\kappa_{CL} + \kappa_{PL}) A_P$$
(2b)

$$\frac{dA_L}{dt} = \kappa_{PL}A_P - \kappa_{LP}A_L \tag{2c}$$

579

578

We used Monolix and a mixed-effect population approach to estimate the parameters and their standard deviations. With the initial condition of  $(A_{GI} = Dose, A_p = 0, A_L =$ 0); we fit  $C_P = \frac{A_P}{Vol}$  to the plasma concentration data where *Vol* is the estimated plasma volume. Details on parameter distributions and the error model provided in **Table S2**.

584

#### 585 PD model

586 For the pharmacodynamics model we used Hill equation,  $\epsilon(t) = \frac{E_{max}C(t)^n}{C^{(t)n} + IC_{50}^n}$ , where C(t)

is the drug's concentration in plasma,  $E_{max}$  is the maximum efficacy, *n* is the Hill coefficient, and  $IC_{50}$  is the drug concentration in plasma required for 50% efficacy. We used least-squared fitting to obtain the three parameters ( $E_{max}$ , *n*, and  $IC_{50}$ ) and their standard deviations. The average drug efficacy is measured using,

$$E_{ave} = \frac{1}{t_{start} - t_{end}} \int_{t_{start}}^{t_{end}} \epsilon(t) dt$$
(3)

592 Where  $t_{start}$  and  $t_{end}$  are the treatment start day and end day, respectively.

593

591

#### 594 Combined PKPD and VL models

595 The plasma concentration of nirmatrelvir obtained from the PK model is used in the PD 596 model to obtain time-dependent efficacy.  $\epsilon(t)$ , then, is used to reduce viral production 597 rate,  $\pi$ , with the factor of  $(1 - \epsilon(t))$ . Equation 1e is written as,

598 
$$\frac{dV}{dt} = (1 - \epsilon(t))\pi I_P - \gamma V \tag{4}$$

#### 599 Fitting the combined model to individual viral load data in the PLATCOV trial

We used the population mixed-effect approach and Monolix to estimate each 600 individual's viral dynamics parameters and the potency reduction factor (prf). Due to 601 the lack of data from the initial phase of infection in the PLATCOV trial, we include 602 the data from Omicron-infected individuals in the NBA cohort to inform the model 603 about the initial phase of infection. We fixed the PK parameters to the estimated 604 population values (Table S2), and the PD parameters other than IC50 to the *in vitro* 605 estimated population values (Table S4). We used the study category (NBA vs 606 PLATCOV) as a covariate for  $t_0$  (timing of infection) and  $\tau$  (timing of the adaptive 607 608 immune response) since the first recorded positive test is likely much later for the clinical trials. In the NBA study, samples were collected almost daily regardless of 609 symptoms often leading to pre-symptomatic detection, while in the PLATCOV study, 610 the baseline measurement occurred after symptom onset, trial enrollment and consent. 611

#### 612 **Construction of a virtual cohort**

To generate a cohort for our simulated clinical trials, we randomly selected 400 613 individuals (for each arm of the simulated trials) from the unvaccinated symptomatic 614 615 subpopulation of the NBA cohort for EPIC-HR and vaccinated with Omicron infection for PLATCOV and used their individual viral load parameters estimated by fitting our 616 viral dynamics model to the data. A sample size of n=400 (out of 822 vaccinated 617 individuals with Omicron infection) was used to mimic a large-scale clinical trial and 618 maintain relatively low overlap between virtual cohorts used in each arm of the 619 simulations and between different simulations. Since the time of symptom onset is not 620 available for all individuals in the NBA data, we randomly drew an incubation period 621 for each individual from gamma distributions with variant-specific parameters 622 estimated by Gamiche et al.<sup>27</sup> The start of treatment relative to symptom onset was 623 randomly selected according to a uniform distribution, except when constructing Fig. 8. 624 The PK parameters of each simulated individual were randomly drawn from lognormal 625 distributions, for which estimated mean and standard deviation were inferred from the 626 PK data. The relevant dose in each scenario was added to the  $A_{GI}$  compartment (the 627 628 ..., 4.5 days). For all doses, we used the PK parameter distributions estimated for 250 629

630 mg since our analysis showed they are dose-independent. PD parameters were also 631 randomly drawn from a normal distribution with the estimated mean and standard 632 deviation. The standard deviation of the PD parameters represents the accuracy of the 633 assays and not individual variability. The individual potency reduction factors were 634 also drawn from a lognormal distribution with estimated mean and standard deviation 635 obtained from fitting the model to the individual viral load data of PLATCOV study.

#### 636 **Potency reduction factor (prf)**

637 The prf is defined as,

$$prf = \frac{IC_{50,in\,vivo}}{IC_{50,in\,vitro}} \tag{5}$$

639

638

640 We estimated the prf by maximizing  $R^2$  when fitting the change in viral load of the 641 treatment arm of our simulation to the data from the treatment arm of the clinical trial.

#### 642 Measuring rebound probability

A viral load rebound in the treatment arm was defined when the viral load at any time after treatment ended exceeded the viral load at the end of the treatment by 1 log. In the control group, viral rebound was defined in patients who had at least two peaks with maximum height of 1000 copies/ml in their viral load trajectories and the second peak was 1 log higher than its preceding local minimum (Fig S7).

648 649

#### 650 **References**

- 651
- Hammond, J. *et al.* Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. *N Engl J Med* 386, 1397–1408 (2022).
- Emergency Use Authorization for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) Center for Drug Evaluation and Research (CDER) Review. *Foods and Drug Administration* (2021).
- 655 Bridg Evaluation and Research (CDER) Review Pools and Drug Hammistration (2021).
  656 Khunte, M., Kumar, S., Salomon, J. A. & Bilinski, A. Projected COVID-19 mortality reduction from paxlovid
  657 rollout. JAMA Health Forum 4, E230046 (2023).
- **458** FDA approves first oral antiviral for treatment of COVID-19 in adults. *Foods and Drug Administration*
- https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19 adults.
- 661 Schilling, W. H. K. et al. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with
- 662 early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. *Lancet* 663 *Infect Dis* 24, 35–45 (2023).
- 664 Pandit, J. A. *et al.* The Coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and
- symptom rebound differences in participants treated with nirmatrelvir plus ritonavir versus untreated controls.
   *Clinical Infectious Diseases* 77, 25–31 (2023).
- 667 Wong, C. K. H. *et al.* Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or
- diagnosis: target trial emulation. *Nat Commun* **14**, (2023).
- Wang, L. *et al.* COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. *medRxiv* (2022)
   doi:10.1101/2022.06.21.22276724.
- Anderson, A. S., Caubel, P. & Rusnak, J. M. Nirmatrelvir–ritonavir and viral load rebound in Covid-19. *N Engl J Med* 387, 1047–1049 (2022).
- **673** Pfizer shares top-line results from phase 2/3 EPIC-PEP study of PAXLOVID<sup>TM</sup> for post-exposure prophylactic
- use. *Pfizer* https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase 23-epic-pep-study.
- 676 Merck provides update on phase 3 MOVe-AHEAD trial evaluating LAGEVRIO<sup>TM</sup> (molnupiravir) for post-
- 677 exposure prophylaxis for prevention of COVID-19 Merck.com. https://www.merck.com/news/merck-provides-
- 678 update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-
- 679 prevention-of-covid-19/.

- 680 Hirsch, C. *et al.* SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. *Cochrane Database*
- 681 Syst Rev Art. No.: CD014945 (2022) doi:10.1002/14651858.CD014945.PUB2.
- 682 O'Brien, M. P. *et al.* Effect of subcutaneous Casirivimab and Imdevimab antibody combination vs placebo on
- development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical
   trial. *JAMA* 327, 432–441 (2022).
- O'Brien, M. P. *et al.* Subcutaneous REGEN-COV antibody combination to prevent Covid-19. *N Engl J Med* 385, 1184–1195 (2021).
- **687** Herman, G. A. *et al.* Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of
- COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* 22, 1444–1454 (2022).
- 690 Su, K. *et al.* A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV
- dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. *PLoS Biol* 19, e3001128 (2021).
- Wang, S. *et al.* Modeling the viral dynamics of SARS-CoV-2 infection. *Math Biosci* **328**, 108438 (2020).
- Perelson, A. S. & Ke, R. Mechanistic modeling of SARS-CoV-2 and other infectious diseases and the effects of
   therapeutics. *Clin Pharmacol Ther* 109, 829–840 (2021).
- **695** Sanche, S. *et al.* A simple model of COVID-19 explains disease severity and the effect of treatments. *Sci Rep* **12**, 14210 (2022).
- 6097 Czuppon, P. et al. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and
- 698 impact of different drug-specific mechanisms of action. *PLoS Comput Biol* **17**, e1008752 (2021).
- 699 Gonçalves, A. *et al.* Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. *CPT* 700 *Pharmacometrics Syst Pharmacol* 9, 509–514 (2020).
- **201** Iwanami, S. *et al.* Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. *PLoS Med* **18**, 25 (2021).
- 203 Goyal, A., Cardozo-Ojeda, E. F. & Schiffer, J. T. Potency and timing of antiviral therapy as determinants of
- duration of SARS-CoV-2 shedding and intensity of inflammatory response. *Sci Adv* 6, (2020).
- **205** Fumagalli, V. *et al.* Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune
- 706 responses. *EMBO Mol Med* **15**, e17580 (2023).
- Perelson, A. S., Ribeiro, R. M. & Phan, T. An explanation for SARS-CoV-2 rebound after Paxlovid treatment.
   *medRxiv* (2023) doi:10.1101/2023.05.30.23290747.
- **269** Owens, K., Esmaeili, S. & Schiffer, J. T. Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses. *JCI Insight* (2024) doi:10.1172/JCI.INSIGHT.176286.
- 201 Galmiche, S. *et al.* SARS-CoV-2 incubation period across variants of concern, individual factors, and
- circumstances of infection in France: a case series analysis from the ComCor study. *Lancet Microbe* 4, E409–
   E417 (2023).
- 284 Finch, C. L. *et al.* Formulation, stability, pharmacokinetic, and modeling studies for tests of synergistic
- combinations of orally available approved drugs against Ebola virus in vivo. *Microorganisms* 9, 566 (2021).
- Mayer, B. T. *et al.* Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.
   *PLoS Comput Biol* 18, (2022).
- 208 Edelstein, G. E. et al. SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy. medRxiv
- 719 2023.06.23.23288598 (2023) doi:10.1101/2023.06.23.23288598.
- 320 Schiffer, J. T., Swan, D. A., Corey, L. & Wald, A. Rapid viral expansion and short drug half-life explain the
- 721 incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. *Antimicrob Agents*
- 722 *Chemother* **57**, 5820–5829 (2013).
- Reeves, D. B. *et al.* Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. *PLoS Comput Biol* **16**, (2020).
- Schiffer, J. T. *et al.* Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. *Sci Transl Med* **8**, (2016).
- Greenfield, S. R. *et al.* Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir. *Xenobiotica* **53**, 12–24 (2023).
- Hau, R. K., Wright, S. H. & Cherrington, N. J. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients. *Clin Transl Sci* **15**, 1599–1605 (2022).
- Wong, C. K. H. *et al.* Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in
- Hong Kong: a population-wide retrospective cohort study. *Lancet Infect Dis* 23, 683–695 (2023).
- Pandit, J. A. *et al.* The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral
- and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated
   Controls. *Clin Infect Dis* 77, (2023).
- 736 Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. & Brosh-Nissimov, T. Nirmatrelvir
- 737 Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged
- 738 Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report.
- 739 *Clinical Infectious Diseases* ciad494, (2023).

- Xu, S. *et al.* Two-way pharmacodynamic modeling of drug combinations and its application to pairs of
- repurposed Ebola and SARS-CoV-2 agents. Antimicrob Agents Chemother (2024) doi:10.1128/AAC.01015-
- 742 23/FORMAT/EPUB.
- Jayk Bernal, A. *et al.* Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. *N Engl J Med* 386,
   509–520 (2022).
- Elias, K. M. et al. Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A
- 746 systematic review and meta-analysis. *medRxiv* 2023.06.18.23291566 (2023) doi:10.1101/2023.06.18.23291566.
- **742**7 Gottlieb, R. L. *et al.* Early Remdesivir to prevent progression to severe Covid-19 in outpatients. *N Engl J Med*
- 748 **386**, 305–315 (2022).
- **749** Carlin, A. F. *et al.* Virologic and immunologic characterization of Coronavirus disease 2019 recrudescence after
- 750 Nirmatrelvir/Ritonavir treatment. *Clin Infect Dis* **76**, E530–E532 (2023).
- **49**1 Epling, B. P. *et al.* Clinical, virologic, and immunologic evaluation of symptomatic Coronavirus disease 2019
- rebound following Nirmatrelvir/Ritonavir treatment. *Clin Infect Dis* **76**, 573–581 (2023).
- **453** Boucau, J. *et al.* Characterization of virologic rebound following Nirmatrelvir-Ritonavir treatment for
- 754 Coronavirus disease 2019 (COVID-19). *Clin Infect Dis* **76**, E526–E529 (2023).
- Lai, C. C. & Hsueh, P. R. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment. *J Med Virol* 95, (2023).
- 757 Hay, J. A. et al. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and
- infection rebound: A retrospective cohort study. *Elife* 11, (2022).
- **AS9** Rohatgi, A. WebPlotDigitizer. vol. 4.7 Software at https://automeris.io/WebPlotDigitizer.html (2024).
- **X60** Singh, R. S. P. *et al.* Innovative randomized phase I study and dosing regimen selection to accelerate and inform
- pivotal COVID-19 trial of Nirmatrelvir. *Clin Pharmacol Ther* **112**, 101–111 (2022).
- **362** Owen, D. R. *et al.* An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.
- 763 *Science* **374**, 1586–1593 (2021).
- Wagoner, J. *et al.* Combinations of host- and virus-targeting antiviral drugs confer synergistic suppression of SARS-CoV-2. *Microbiol Spectr* **10**, (2022).
- Ke, R. *et al.* Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in
- r67 infectiousness HHS Public Access. doi:10.5281/zenodo.6311388.
- 768 769

770

#### 771 Acknowledgments

772

777

786

789

#### 72

#### 773 Funding:

- 774 National Institutes of Health (NIH) grants R01AI169427 (JTS)
- 775 National Institutes of Health (NIH) grants R01AI121129 (JTS)
- 776 National Institutes of Health (NIH) grants R01AI177512 (JTS, SJP)

#### 778 **Author contributions:**

- 779 Conceptualization: JTS, SE, KO
- 780 Methodology: JTS, SE, KO
- 781 Software: SE, KO
- 782 Investigation: SJP, JW, SE, KO
- 783 Formal analysis: SE, KO
- 784 Writing original draft: JTS, SE
- 785 Writing review & editing: JTS, SE, KO, SJP, JW, JMW

#### 787 **Competing interests:**

- 788 Authors declare that they have no competing interests.
- 790 **Data availability:**

- The data analyzed in this work was previously published by Hay et al. and Schilling et 791 al. and is available on github at 792 https://github.com/gradlab/SC2-kinetics-immune-history and 793 https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0 794 Pharmacodynamics data is available on guithub at 795 https://github.com/sEsmaeili/Covid Rebound 796 797 **Code availability:** 798 All codes and materials used in the analysis is available on github at 799 https://github.com/sEsmaeili/Covid Rebound 800 801 802
- 803

#### **Figures and Tables** 804 805 806 (a) Viral Dynamic Model ρ R susceptible (b) PK Model cells SARS-CoV ß drug φ administration plasma tissue Кы eclipse IE Ka $A_{GI}$ infected cells A<sub>L</sub> π к **K**CL PD Model C<sub>P</sub>=A<sub>P</sub>/Vol productive ε(C<sub>P</sub>) IP infected cells drug efficacy δ T cell-mediated m(t) immune cytolysis and response early immune response

807

#### 808 Fig. 1. Schematics of the viral dynamic model and nirmatrelvir PK-PD two

809 compartmental model. (a) The viral dynamic model follows the dynamics of susceptible cells (S), refractory cells (R), eclipse infected cells (I<sub>E</sub>), productively 810 infected cells (I<sub>P</sub>), and virus (V) and includes the early and late cytolytic T-cell immune 811 responses with rates  $\delta$  and m(t).  $\beta$  is the infection rate,  $\phi$  is the rate of conversion of 812 susceptible cells to refractory cells, and  $\rho$  is the rate of reversion of refractory cells to 813 susceptible cells. Infected cells produce viruses at the rate  $\pi$ , and the free viruses are 814 cleared at the rate  $\gamma$ . (b) Two-compartmental PK model with oral administration of the 815 drug which models the amounts of the drug in gut tissue  $(A_{GI})$ , plasma  $(A_P)$ , and the 816 tissue (A<sub>L</sub>).  $K_a$  is the rate of absorption of the drug from gut to plasma.  $K_{PL}$  and  $K_{LP}$  are 817 the rates of transfer of the drug from plasma to the tissue and back, and K<sub>CL</sub> is the rate 818 at which the drug clears from the body. Vol is the estimated plasma volume and  $C_P$  is 819 the drug concentration in plasma.  $\epsilon(C_P)$  is the drug efficacy that blocks viral production 820 and is calculated using the Hill equation:  $\frac{E_{max}C_p^n}{C_p^n + (prf*IC_{50})^n}$  where Emax is the maximum 821 efficacy, n is the Hill coefficient, IC50 is the concentration of drug in vitro at which 822 viral replication rate is reduced by 50%, prf is the potency reduction factor translating 823 824 the *in vitro* potency to *in vivo* potency.




Fig. 2. Lower *in vivo* potency of nirmatrelyir relative to *in vitro* potency in EPIC-HR. (a-b) mean (blue), individual (gray), and ranges (labeled dashed lines) of log10 viral load drop from the baseline of individuals randomly selected from the NBA cohort treated with (a) placebo or (b) five days of nirmatrelvir / ritonavir 300 mg twice daily. The red dots were obtained by digitizing Fig 3a of Hammond et al.<sup>1</sup> and model fit was noted by closeness of blue lines to the red dots. (c)  $R^2$  of the fit of the 10 model simulations per prf to the viral load drop data in light blue and their mean in dark blue. The best model fit was at a potency reduction factor of 61. The horizontal boxplot in the lower panel shows the distribution of prf values at which  $R^2$  is maximum (mean = 61.8, median =61, sd=3.5). (d) Drug efficacy when prf=61. Average efficacy was 82% over the 5-day interval, with notable drops in antiviral efficacy at drug troughs. (e) Projected average drug efficacy when prf = 1 vs prf = 61. The drug with no potency reduction has nearly perfect efficacy (average efficacy of 99.99%) over 5 days and has a prolonged post-treatment effect. (f) Projected mean log10 viral load drop from baseline of the control arm, treatment arm with prf=61, and treatment arm with prf=1.

844 845

826

827

828

829

830

831

832

833

834

835

836


837

838

839

840 841

842



### Fig. 3. Lower *in vivo* potency of nirmatrelvir relative to *in vitro* potency in

PLATCOV. Method I: (a-b) mean (blue), individual (gray), and ranges (labeled dashed lines) of log10 viral load drop from the baseline of individuals randomly selected from the NBA cohort treated with (a) placebo or (b) five days of nirmatrelvir / ritonavir 300 mg twice daily. The empty and filled red circles are individual and mean viral load drop from baseline calculated from viral load data published by Schilling et al.<sup>5</sup>. Model fit was noted by closeness of blue lines to the filled red dots. (c)  $R^2$  of the fit of the 10 model simulations per prf to the viral load drop data in light blue and their mean in dark blue. The best model fit was at a potency reduction factor of 37. The horizontal boxplot in the lower panel shows the distribution of prf values at which R<sup>2</sup> is maximum (mean = 36.6, median = 37, sd = 2.15). (d-e) distribution of log10 viral load drop from baseline of simulated cohort and the 144 individuals in PLATCOV control arm (d) and treatment arm (e). Adjusted p-values (q-values) were calculated using Benjamini-Hochberg method and represent dissimilarity between observed and simulated distributions. Method II: (f-g) sample individual fits to PLATCOV trial participants in control (f) and treatment (g) arms. (h) distribution of estimated individual prf values (center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range, blue dots are the prf values for each individual in the treatment arm). Remaining fits are in Figs S4 and S5.

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867 868




Fig. 4. Increasing the nirmatrelvir dose lowers short-term viral load but increases the probability of viral rebound. In all scenarios, simulated treatment starts within the first 3 days post-symptoms. (a) log10 viral load at days 2, 5, and 10 after the treatment start day with different doses. p-values were obtained by performing two-sided Mann-Whitney U-test between the 300 mg group and the others, and only p-values <0.01 are shown. Viral loads were only reduced by higher doses at days 2 and 5, but not day 10, except for 900 mg. (b) The probability of rebound for different doses. The error bars on each column are 95% confidence intervals. (c) Examples of viral load trajectories assuming different doses on 4 modeled individuals with equivalent timing of therapy and untreated viral kinetics. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range.</p>







Fig. 5. Early timing of therapy initiation is a key risk factor for viral rebound. In all simulations, the dose was 300 mg twice daily for five days. PEP = 0 to 1 day after infection, early = 1-3 days after symptom onset, intermediate = 3-5 days after symptom onset, and late = 5-10 days after symptom onset. (a) log10 viral load at days 2, 5, and 10 after the treatment start day with different treatment durations. p-values were obtained by performing two-sided Mann-Whitney U-test. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range. (b) The probability of rebound for different treatment timing. The error bars on each column are 95% confidence interval (c) Samples of viral load trajectories assuming different treatment timing on 4 modeled individuals with equivalent untreated viral kinetics.



905
906
907
908
909
910
911
912
913
914
915

916

917

918 919

904

Fig. 6. Prolonging treatment duration limits rebound probability. In all simulations, treatment starts within the first 3 days post-symptoms and the dose was 300 mg twice daily. (a) log10 viral load at days 2, 5, and 10 after the treatment start day with different treatment durations. p-values were obtained by performing two-sided Mann-Whitney U-test and only values <0.01 are shown. At day 10, the control group had equivalent viral loads to 2 days of treatment while 5 or 10 days of treatment significantly lowered viral load. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range. (b) The probability of rebound for different treatment durations. The probabilities of rebound after 15 and 20 days of treatment were zero. The error bars on each column are 95% confidence interval. (c) Samples of viral load trajectories assuming different treatment durations on 4 modeled individuals with equivalent timing of therapy and untreated viral kinetics. Prolonging therapy often avoids rebound.</li>







Fig. 7. Post-exposure prophylaxis requires more prolonged therapy than early symptomatic therapy to avoid viral rebound. (a) probability of rebound and (b) viral load at the end of the treatment as a function of treatment timing and duration.



# Fig. 8. Early therapy preserves susceptible cells, limits refractory cells, does not eliminate all infected cells, and delays innate immune responses.

Simulations are performed using time since infection as a variable rather than based on symptoms as in prior figures to eliminate the confounding impact of variable incubation period. (a) The top row shows the viral load of all individuals (in grey) and the average viral load (in blue). The middle row shows a less substantial depletion of susceptible cells (S, in green) and a lower generation of refractory cells (R, in red) with earlier therapy. The infected cells (I) are shown in blue. The highlighted area around each line (not visible) shows the 95% confidence interval. The bottom row shows the rate of production of refractory cells, which likely represents innate immune responses per day. The biphasic immune response with a lower initial peak and a second one after the end of the treatment is observed with early therapy and is present to a lesser extent in day 4 treated individuals. The highlighted areas show 95% confidence intervals. (b) Ratios of susceptible (S) to refractory cells (R) at the end of the 5day treatment for different timings of treatment. (c) Per cell production rate of refractory cells at the end of the 5-day treatment for different timings of treatment. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range. p-values were obtained by performing two-sided Mann-Whitney U-test (\*: 0.01 ,\*(0.001

950 951

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943 944

945

946

947

948

949